2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Zoetis Inc. company profile · business segments · history · financial snapshot · S&P 500 rank #303 · 碩騰公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | ZTS |
| Company | Zoetis Inc. |
| GICS sector / industry | Health Care (XLV) / Pharmaceuticals |
| S&P 500 rank (by weight) | #303 · 0.05% (Nov 3, 2026) |
| Sector rank | #39 of 60 in Health Care (Nov 3, 2026) |
| Headquarters | Parsippany, New Jersey |
| Founded | 1952 (2013) |
| CEO | Kristin C. Peck (Chief Executive Officer) |
| Employees | 14,500 (2025) |
| Market cap | $34.26B (Nov 3, 2026) |
| Share price | $82.74 (Nov 3, 2026) |
| SEC filings | EDGAR — CIK 0001555280 |
WHAT IT DOES
Zoetis Inc. is the world's largest animal-health company, headquartered in Parsippany, New Jersey. It develops, manufactures and sells medicines, vaccines, diagnostics and genetic tests for pets and farm animals, a business that began in 1952 as Pfizer's animal-health division and became independent in 2013.
Its one-line model: sell innovative, patent-protected animal medicines through veterinarians and producers, led by companion-animal franchises — Simparica parasiticides, Apoquel and Cytopoint dermatology products, and the Librela and Solensia osteoarthritis antibodies. Companion animals supplied $6.59B of fiscal 2025 revenue of $9.47B.
Zoetis is a steady compounder: fiscal 2025 revenue rose to $9,467M from $9,256M, net income rose to $2,673M from $2,486M, and diluted EPS rose to $6.02 — growth led by pet care, partly offset by a decline in U.S. livestock revenue to $877M from $1,020M.
BUSINESS SEGMENTS
| United States | U.S. companion animal revenue of $4,220M and livestock revenue of $877M — fiscal 2025 segment revenue of $5,097M, about 54% of the total. |
| International | International companion animal revenue of $2,367M and livestock revenue of $1,887M — fiscal 2025 segment revenue of $4,254M. |
| Contract manufacturing & human health | Contract manufacturing and human-health products (a legacy Pfizer activity) — fiscal 2025 revenue of $116M. |
HISTORY
| Year | Milestone |
|---|---|
| 1952 | Zoetis's origins: Pfizer builds its agricultural and animal-health division, the business that becomes Zoetis. |
| 2013 | Zoetis lists on the NYSE in February 2013 in the largest U.S. IPO since Facebook at the time; Pfizer completes the separation in June 2013 through an exchange offer. |
| 2018 | Zoetis acquires Abaxis for about $2.0B, adding point-of-care veterinary diagnostics. |
| 2020 | Kristin C. Peck becomes chief executive officer (January 1, 2020). |
| 2023 | Librela — the first monoclonal antibody for osteoarthritis pain in dogs — launches in the United States, extending the pet-dermatology and pain franchises. |
| 2025 | Revenue reaches $9.47B with net income of $2.67B, companion animals supplying about 70% of revenue. |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT
| Total revenue | $9.47B (FY2025 revenue) |
| Income before income taxes | $3.36B (FY2025 pre-tax income) |
| Net income | $2.67B (FY2025 net income) |
| Diluted EPS | $6.02 (FY2025 diluted EPS) |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Zoetis is a small-weight health-care constituent: rank #303 by weight at 0.05% as of Nov 3, 2026, and #39 in Health Care. As the index's only pure-play animal-health major, it isolates pet-care and livestock economics from human pharma.
SOURCES & METHODOLOGY
| Financials, segments, headquarters | Zoetis Inc. fiscal 2025 Form 10-K data via SEC EDGAR (see Financial Snapshot note); headquarters, CEO and employees via the Form 10-K and Wikipedia company profile |
| Index weight & ranks | Slickcharts S&P 500 weights, fetched Nov 3, 2026; sector membership per Wikipedia List of S&P 500 companies (GICS) |
| Market cap | $34.26B (Slickcharts, Nov 3, 2026) |
| Logo | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. |
| Chart | SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 股票代號 | ZTS |
| 公司 | Zoetis Inc.(碩騰) |
| GICS 板塊/行業 | 醫療保健(XLV)/製藥 |
| 標普500排名(按權重) | #303 · 0.05%(Nov 3, 2026) |
| 板塊內排名 | 醫療保健 #39(共 60 家)(Nov 3, 2026) |
| 總部 | 美國新澤西州帕西波尼 |
| 成立 | 1952年(2013年獨立) |
| 執行長 | Kristin C. Peck(執行長) |
| 員工 | 14,500(2025年) |
| 市值 | $34.26B(Nov 3, 2026) |
| 股價 | $82.74(Nov 3, 2026) |
| SEC 申報 | EDGAR — CIK 0001555280 |
業務概覽
碩騰是全球最大的動物保健公司,總部位於美國新澤西州帕西波尼。公司研發、生產與銷售寵物及農場動物的藥物、疫苗、診斷產品與基因檢測,業務源於 1952 年輝瑞的動物保健部門,2013 年獨立。
其一句話商業模式是:透過獸醫與生產者銷售具專利保護的創新動物藥物,以伴侶動物系列領軍——Simparica 驅蟲藥、Apoquel 與 Cytopoint 皮膚科產品,以及 Librela 與 Solensia 骨關節炎抗體藥。伴侶動物於 2025 財年收入 94.67 億美元中佔 65.87 億美元。
碩騰是穩定的複合增長者:2025 財年收入由 92.56 億美元增至 94.67 億美元,淨利潤由 24.86 億美元增至 26.73 億美元,稀釋 EPS 升至 6.02 美元——增長由寵物護理帶動,部分被美國畜禽收入由 10.20 億美元降至 8.77 億美元抵銷。
業務板塊
| 美國 | 美國伴侶動物收入 42.20 億美元、畜禽收入 8.77 億美元——2025 財年板塊收入 50.97 億美元,約佔總額 54%。 |
| 國際 | 國際伴侶動物收入 23.67 億美元、畜禽收入 18.87 億美元——2025 財年板塊收入 42.54 億美元。 |
| 合約製造與人類健康 | 合約製造與人類健康產品(源於輝瑞的遺留業務)——2025 財年收入 1.16 億美元。 |
歷史
| 年份 | 里程碑 |
|---|---|
| 1952 | 碩騰的源頭:輝瑞建立其農業與動物保健部門,即日後成為碩騰的業務。 |
| 2013 | 碩騰於 2013 年 2 月在紐約證券交易所上市,是當時自 Facebook 以來最大規模的美國 IPO;輝瑞於 2013 年 6 月透過換股要約完成分拆。 |
| 2018 | 碩騰以約 20 億美元收購 Abaxis,加入即時獸醫診斷業務。 |
| 2020 | Kristin C. Peck 出任執行長(2020 年 1 月 1 日)。 |
| 2023 | Librela——首個用於犬隻骨關節炎疼痛的單株抗體藥——在美國推出,擴展寵物皮膚科與疼痛系列。 |
| 2025 | 收入達 94.67 億美元,淨利潤 26.73 億美元,伴侶動物佔收入約 70%。 |
競爭地位
財務快照
| 總收入 | $9.47B(FY2025 收入) |
| 稅前利潤 | $3.36B(FY2025 稅前利潤) |
| 淨利潤 | $2.67B(FY2025 淨利潤) |
| 稀釋 EPS | $6.02(FY2025 稀釋 EPS) |
主要風險
對標普500的重要性
碩騰是權重較小的醫療保健成分股:按權重排名 #303,權重 0.05%(以 2026 年 11 月 3 日為準),醫療保健板塊內排名 #39。作為指數中唯一的純動物保健大型股,它將寵物護理與畜禽經濟從人類製藥中分離出來。
來源與方法
| 財務、板塊、總部 | 碩騰 2025 財年 Form 10-K 數據,經 SEC EDGAR(見財務快照附註);總部、執行長與員工經 Form 10-K 及維基百科公司資料 |
| 指數權重與排名 | Slickcharts 標普 500 權重,Nov 3, 2026 抓取;板塊歸屬按維基百科標普 500 成分股名單(GICS) |
| 市值 | $34.26B(StockAnalysis,Nov 3, 2026) |
| Logo | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 |
| 股價圖 | SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月線(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份)· SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-03 10:52 · updated 2026-11-15 00:21 · rev 6